| United States valuation of EQ-5D-5L health states using an international protocol AS Pickard, EH Law, R Jiang, E Pullenayegum, JW Shaw, F Xie, M Oppe, ... Value in health 22 (8), 931-941, 2019 | 238 | 2019 |
| Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research EH Law, M Leung Annals of Pharmacotherapy 49 (3), 335-342, 2015 | 78 | 2015 |
| Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 75 | 2020 |
| Association between proton pump inhibitors and microscopic colitis: implications for practice and future research EH Law, M Badowski, YT Hung, K Weems, A Sanchez, TA Lee Annals of Pharmacotherapy 51 (3), 253-263, 2017 | 50 | 2017 |
| Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study Z Zhou, P Chaudhari, H Yang, AP Fang, J Zhao, EH Law, EQ Wu, R Jiang, ... Diabetes Therapy 8, 555-571, 2017 | 42 | 2017 |
| Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis EM Salvo, AO Ramirez, J Cueto, EH Law, A Situ, C Cameron, IA Samjoo The Breast 57, 5-17, 2021 | 31 | 2021 |
| Parallel valuation: a direct comparison of EQ-5D-3L and EQ-5D-5L societal value sets EH Law, AS Pickard, F Xie, SM Walton, TA Lee, A Schwartz Medical Decision Making 38 (8), 968-982, 2018 | 28 | 2018 |
| Racial and ethnic differences in risk of second primary cancers among breast cancer survivors GS Calip, EH Law, NY Ko Breast cancer research and treatment 151, 687-696, 2015 | 26 | 2015 |
| A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017 AS Cha, EH Law, JW Shaw, AS Pickard Quality of Life Research 28, 3065-3069, 2019 | 15 | 2019 |
| Target-specific oral anticoagulants in patients undergoing cardioversion EH Law, W Gordon American journal of health-system pharmacy 71 (14), 1171-1176, 2014 | 15 | 2014 |
| A primer on latent class analysis EH Law, R Harrington Value & Outcomes Spotlight 2 (6), 18-19, 2016 | 12 | 2016 |
| Health-related quality of life among patients with HR+/HER2–early breast cancer C Criscitiello, D Spurden, J Piercy, A Rider, R Williams, D Mitra, R Wild, ... Clinical Therapeutics 43 (7), 1228-1244. e4, 2021 | 11 | 2021 |
| Clinical trajectories, healthcare resource use, and costs of diabetic nephropathy among patients with type 2 diabetes: a latent class analysis R Jiang, E Law, Z Zhou, H Yang, EQ Wu, R Seifeldin Diabetes therapy 9, 1021-1036, 2018 | 11 | 2018 |
| Increasing uptake of comparative effectiveness and patient-centered outcomes research among stakeholders: insights from conference discussion E Law, R Harrington, GC Alexander, S Saha, E Oehrlein, EM Perfetto Journal of comparative effectiveness research 7 (2), 181-191, 2018 | 9 | 2018 |
| Choice blindness and health-state choices among adolescents and adults EH Law, AL Pickard, A Kaczynski, AS Pickard Medical Decision Making 37 (6), 680-687, 2017 | 8 | 2017 |
| Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: Is early treatment associated with improved outcomes? P Chaudhari, C Vallarino, EH Law, R Seifeldin Diabetes Research and Clinical Practice 122, 162-169, 2016 | 8 | 2016 |
| Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial M Hordinsky, AA Hebert, M Gooderham, O Kwon, N Murashkin, H Fang, ... Pediatric Dermatology 40 (6), 1003-1009, 2023 | 7 | 2023 |
| Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the Ibrance real world insights study K Mycock, KA Hanson, G Taylor-Stokes, G Milligan, C Atkinson, D Mitra, ... Clinical Therapeutics 44 (12), 1588-1601, 2022 | 7 | 2022 |
| Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment K Beusterien, MC Maculaitis, B Hallissey, MM Gaschler, ML Smith, ... Patient preference and adherence, 611-623, 2021 | 7 | 2021 |
| Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran TS Leung, EH Law Drug Design, Development and Therapy, 3557-3569, 2015 | 7 | 2015 |
A. Simon PickardUniversity of Illinois, ChicagoVerified email at uic.edu
